Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Enanta Pharmaceuticals stock in Canada | $48.66

Own Enanta Pharmaceuticals shares in just a few minutes.

Enanta Pharmaceuticals, Inc
NASDAQ: ENTA - USD
BIOTECHNOLOGY
$42.49
-$0.23 (-0.54%)
Avatar
Jing Jun Ma
Updated . What changed?
Fact checked

Enanta Pharmaceuticals is a biotechnology business based in the US. Enanta Pharmaceuticals stocks (ENTA.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $42.72 – an increase of 1.02% over the previous week. Enanta Pharmaceuticals employs 141 staff and has a trailing 12-month revenue of around $94.2 million.

How to buy Enanta Pharmaceuticals stock in Canada

  1. Choose a platform. If you're a beginner, our stock trading table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: ENTA in this case.
  5. Research Enanta Pharmaceuticals stocks. The platform should provide the latest information available.
  6. Buy your Enanta Pharmaceuticals stocks. It's that simple.

What's in this guide?

  1. Can I buy shares in Enanta Pharmaceuticals?
  2. Has coronavirus impacted Enanta Pharmaceuticals shares?
  3. Enanta Pharmaceuticals shares summary
  4. Compare share dealing platforms
  5. Is Enanta Pharmaceuticals stock a buy or sell?
  6. Enanta Pharmaceuticals performance over time
  7. Can I short Enanta Pharmaceuticals shares?
  8. Enanta Pharmaceuticals's financials
  9. How volatile are Enanta Pharmaceuticals shares?
  10. Does Enanta Pharmaceuticals pay a dividend?
  11. Other common questions

How has Coronavirus impacted Enanta Pharmaceuticals's stock price?

Since the stock market crash in March caused by coronavirus, Enanta Pharmaceuticals's stock price has had significant negative movement.

Its last market close was $48.66, which is 8.53% down on its pre-crash value of $53.2 and 26.72% up on the lowest point reached during the March crash when the stocks fell as low as $38.4.

If you had bought $1,000 worth of Enanta Pharmaceuticals stocks at the start of February 2020, those stocks would have been worth $869.91 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $921.62.

Enanta Pharmaceuticals stock price

Use our graph to track the performance of ENTA stocks over time.

Enanta Pharmaceuticals stocks at a glance

Information last updated 2021-07-23.
Latest market close$48.66
52-week range$40.32 - $56.97
50-day moving average $45.255
200-day moving average $48.7432
Wall St. target price$68.14
Dividend yield N/A (0%)
Earnings per share (TTM) $0.119

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available Asset Types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
Wealthsimple Trade
OFFER
Wealthsimple Trade
Stocks, ETFs
$0
N/A
$0
Free
Get a $50 bonus when you open a Wealthsimple Trade account and deposit and trade at least $100.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Go to site
More Info
Scotia iTRADE
Scotia iTRADE
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
$4.99-$9.99
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$0
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
Go to site
More Info
CIBC Investor's Edge
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$6.95
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Go to site
More Info
Interactive Brokers
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
$0
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Go to site
More Info
Questrade
Questrade
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$4.95-$9.95
$9.95 + $1 per contract
$0
Free
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Go to site
More Info
Qtrade Direct Investing
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Trade 100 select ETFs free of charge.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.
Go to site
More Info
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy Enanta Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Enanta Pharmaceuticals price performance over time

Historical closes compared with the last close of $48.66

1 month (2021-06-30) 10.57%
3 months (2021-04-30) -4.10%

Is Enanta Pharmaceuticals under- or over-valued?

Valuing Enanta Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Enanta Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Enanta Pharmaceuticals's EBITDA

Enanta Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$14.8 million.

The EBITDA is a measure of a Enanta Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Enanta Pharmaceuticals financials

Revenue TTM USD$94.2 million
Gross profit TTM USD$122.5 million
Return on assets TTM -10.78%
Return on equity TTM -16.05%
Profit margin -78.57%
Book value $21.602
Market capitalisation USD$828.4 million

TTM: trailing 12 months

How to short and sell Enanta Pharmaceuticals stocks

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "ENTA.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 1.7 million Enanta Pharmaceuticals stocks held short by investors – that's known as Enanta Pharmaceuticals's "short interest". This figure is 6.8% down from 1.9 million last month.

There are a few different ways that this level of interest in shorting Enanta Pharmaceuticals stocks can be evaluated.

Enanta Pharmaceuticals's "short interest ratio" (SIR)

Enanta Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Enanta Pharmaceuticals stocks currently shorted divided by the average quantity of Enanta Pharmaceuticals stocks traded daily (recently around 165821.7349857). Enanta Pharmaceuticals's SIR currently stands at 10.49. In other words for every 100,000 Enanta Pharmaceuticals stocks traded daily on the market, roughly 10490 stocks are currently held short.

However Enanta Pharmaceuticals's short interest can also be evaluated against the total number of Enanta Pharmaceuticals stocks, or, against the total number of tradable Enanta Pharmaceuticals stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Enanta Pharmaceuticals's short interest could be expressed as 0.09% of the outstanding stocks (for every 100,000 Enanta Pharmaceuticals stocks in existence, roughly 90 stocks are currently held short) or 0.121% of the tradable stocks (for every 100,000 tradable Enanta Pharmaceuticals stocks, roughly 121 stocks are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the stock price and a discouraging interest in betting against Enanta Pharmaceuticals.

Find out more about how you can short Enanta Pharmaceuticals stock.

Enanta Pharmaceuticals stock dividends

We're not expecting Enanta Pharmaceuticals to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.

Enanta Pharmaceuticals stock price volatility

Over the last 12 months, Enanta Pharmaceuticals's stocks have ranged in value from as little as $40.32 up to $56.97. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Enanta Pharmaceuticals's is 0.3836. This would suggest that Enanta Pharmaceuticals's stocks are less volatile than average (for this exchange).

Enanta Pharmaceuticals overview

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company offers glecaprevir for the treatment of chronic hepatitis C virus, or HCV under the MAVYRET and MAVIRET names. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.

Stocks similar to Enanta Pharmaceuticals

AbbVie Inc

AbbVie Inc

$118.87

+$0.32 (0.27%)

Enanta Pharmaceuticals in the news

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site